Clinical Trial Search

Primary: Percentage of Participants Who Achieved a ≥4 Point Reduction in Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) 2000 (2K) Score at Week 24 — 20; 27; 22; 22…

Primary: Change in ESSDAI Total Score — -3.77; -5.54; 11.52; 13.12 score on a scale

Primary: Montgomery Asberg Depression Rating Scale (MADRS) Score Change — -21.7; -14.6 summed total scores — p==0.040

Primary: Change From Baseline in WOMAC Pain Subscale Score at Week 4/EOT — -5.4; -5.2 score on a scale — p=0.6742

Primary: Pharmacokinetic (PK): AUCd15 and AUCtau of Crizanlizumab at 5.0 mg/kg in Sickle Cell Disease (SCD) Patients — 13100; 20800 hr*μg/mL

Primary: Number of Participants With Adverse Events (AEs) — 16; 7; 0; 1 Participants

Primary: Change From Baseline in WOMAC Pain Subscale at Week 12 — -0.83; -0.64; -0.47 score on a scale

Primary: Best Overall Response Rate (BORR) — 36.4 percentage of participants

Primary: Number of Participants With Treatment-emergent Adverse Events (AEs) or Serious Adverse Events (SAEs) — 9; 5; 10; 5 Participants

Primary: Proportion of Patients Who Achieve an Investigator's Global Assessment (IGA) Score of 0 (Clear) or 1 (Almost Clear) at Week 16. — 2 Participants

Primary: Overall Response Rate (ORR) Per Independent Review Committee (IRC) in Main Cohort — 54.5 Percentage of participants

Primary: Change From Baseline at Week 12 in Ocular Pain Severity Visual Analog Scale (VAS) — -23.7; -21.7; -25.3 Scores on a scale — p=0.930

Primary: Percentage of Participants Reporting Solicited Local Reactions Within 7 Days After Vaccination in Each Age Group — 56.3; 81.3; 81.3; 93.8 percentage of participants

Primary: Change From Baseline in the Clinician-Administered PTSD Total Symptom Severity Score — 35.5; 33.8; -6.8; -10.3 Score on a Scale

Primary: Safety - Adverse Events Including Serious Adverse Events — 1; 1 Participants — p=1.000